Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $999.36M
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 1.10M
Average 0.87M
GPCR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Structure Therapeutics Inc.NASDAQ: GPCR
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $182.13M (cash outflow) rose 195.4% year over year, ahead of the +62.6% change in trailing-twelve-month net income. Sequentially, it rose 139.0% from the prior quarter. Over 3 fiscal years it compounded at +40.1% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$87.09M (-38.3%) for the fiscal year ending Dec 2026, a slowdown from the +15.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$182.13M+139.0% QoQ
- Last fiscal yearDec 2025
- -$141.2M+15.2% YoY
- LTMJun 2026
- -$291.03M+62.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +195.4% | -72.2% | -267.6 pp |
| 1 year | +15.2% | -38.3% | -53.6 pp |
| 3-year CAGR | +40.1% | -35.4% | -75.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (141.2M) USD
- Year-over-year change
- -15.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (141.2M) | -15.2% |
| FY2024 | 2024-12-31 | (122.53M) | -36.7% |
| FY2023 | 2023-12-31 | (89.62M) | -74.6% |
| FY2022 | 2022-12-31 | (51.32M) | -34.9% |
| FY2021 | 2021-12-31 | (38.05M) | — |
Net Income vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's LTM Jun 2026 net income of $291.03M is the 2nd largest of the 8 companies compared; the peer median is $89.93M.
- Its year-over-year change of +62.6% is the 3rd highest of 7, against a peer median of +13.5%.
- Over three fiscal years its annual growth of +40.1% compares with a peer median of +19.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $349.58M | +83.2% | +73.1% | — | |
| LTM Jun 2026 | $291.03M | +62.6% | +40.1% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | $148.96M | — | — | — |
| LTM Mar 2026 | $122.54M | -335.9% | +4.5% | 612.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $89.93M | +26.6% | +26.6% | 871.8% |
SEPNSepterna, Inc. | LTM Sep 2026 | $59M | +0.3% | +20.9% | 61.3% |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $918K | +104.2% | +17.5% | 2.5% | |
| Peer median (excluding GPCR) | $89.93M | +13.5% | +19.2% | 337.0% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (38.05M) | (51.32M) | (89.62M) | (122.53M) | (141.2M) |
| Depreciation & Amortization | 72K | 277K | 295K | 992K | 1.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.49M | 2.51M | 8.19M | 18.79M | 28.99M |
| Change in Working Capital | 4.06M | 2.97M | 6.97M | 2.96M | (88.27M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.9M | 2.15M | (859.25K) | 3.31M | 4.77M |
| Other Working Capital | 2.17M | 815K | 7.83M | (343K) | (93.05M) |
| Other Non-Cash Items | 268K | (558K) | (5.32M) | (16.86M) | (23.05M) |
| Operating Cash Flow | (32.16M) | (46.12M) | (79.49M) | (116.64M) | (222.2M) |
| Capital Expenditures | (1.21M) | (155K) | (2.17M) | (1.29M) | (3.61M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (4.21M) | (123.45M) | (416.99M) | (702.52M) | (547.38M) |
| Sales of Investments | 23.28M | 61.5M | 151.05M | 344.9M | 630.54M |
| Other Investing Activities | 0 | 0 | (231.38K) | 0 | 10.25M |
| Investing Cash Flow | 17.86M | (62.11M) | (268.34M) | (358.91M) | 89.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 472.3M | 514.57M | 767.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (104K) | (2.49M) | (20.77M) | 690K | (4.66M) |
| Financing Cash Flow | 103.25M | 29.01M | 451.53M | 515.26M | 762.52M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.66M) |
| Net Change in Cash | 88.95M | (79.21M) | 103.7M | 39.72M | 630.12M |
| Free Cash Flow | (33.37M) | (46.28M) | (81.66M) | (117.93M) | (225.81M) |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$17.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.